A Study Investigating Pembrolizumab in Combination With Eribulin in TNBC

January 3, 2017
Sara Tolaney, MD, MPH

Sara Tolaney, MD, MPH, associate clinical research director of Breast Oncology at the Dana-Farber Cancer Institute in Boston, discusses a clinical trial investigating pembrolizumab in combination with eribulin in triple-negative breast cancer.